HOME >> BIOLOGY >> NEWS
Preventing graft-versus-host disease disease after bone marrow transplant -- without toxicity

Unless the donor is an identical twin, patients undergoing bone-marrow transplant (also known as hematopoietic stem cell transplant, or HSCT) must first receive powerful chemotherapy drugs to wipe out their immune system and prevent their bodies from rejecting the donated cells. Research from Childrens Hospital Boston and the Dana-Farber Cancer Institute has helped demonstrate that this punishing regimen increases the risk of graft-versus-host disease (GVHD), in which the donors cells mount an immune response against the patient. But the most recent findings also suggest that the risk for GVHD can be reduced by replacing a natural antibiotic protein, known as bactericidal/permeability increasing protein (BPI), which is depleted when patients undergo chemotherapy.

Now, a multicenter study is about to test this idea in HSCT patients, using a manufactured form of BPI known as rBPI21 (XOMA Ltd.) Unlike other treatments to prevent GVHD, BPI does not suppress the immune system and has shown virtually no toxicity.

Researchers Ofer Levy, MD, PhD, of Childrens Hospital Boston, and Eva Guinan, MD, of Childrens Hospital Boston and Dana-Farber Cancer Institute, will present their most recent findings and discuss the new clinical trial on December 11 at the American Society of Hematology (ASH) Annual Meeting in Orlando, Fla. (abstract # 2856).

The new trial is the culmination of over five years of collaborative research by Levy and Guinan in human patients. "Many basic and translational studies, including our own, have provided a strong rationale for a trial of BPI in patients undergoing hematopoietic stem cell transplants," says Levy. "Replenishing a natural host defense factor that is deficient due to chemotherapy makes theoretical and practical sense, and we hope that bringing our bench work to patients will reduce the complications they suffer."

GVHD occurs when immune cells from donor attack the recipient, and can lead to multiple
'"/>

Contact: Anna Gonski
anna.gonski@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
11-Dec-2006


Page: 1 2 3

Related biology news :

1. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts
2. Preventing cancer without killing cells
3. Preventing obesity in children -- research highlights physical activity levels
4. Preventing ventilation induced lung injury depends on giving the right number of sighs
5. Preventing bacterial biofilms could help fight TB
6. Preventing fetal exposure to popular acne drug
7. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
8. Size matters: Preventing large mammal extinction
9. Preventing muscle atrophy
10. Undesirable expatriates: Preventing the spread of invasive animals
11. Preventing SCD1 expression prevents obesity

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2020)... (PRWEB) , ... June 24, 2020 , ... ... cloud-based enterprise software and software-driven clinical data services that accelerate drug development, is ... low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is ...
(Date:6/23/2020)... ... , ... The field of quantitation of large molecules or proteins has been ... However, the use of mass spectrometry in this field has gained a lot of ... you choose which approach to use (LBA or MS)?” In many cases, either ...
(Date:6/19/2020)... ... , ... The director of stem cell biotechnology company Asymmetrex , Dr. ... pharmaceutical industries have easier access to stem cell counting, they will soon make it ... Independence Day weekend in the U.S., Asymmetrex is offering free tissue stem cell counting ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... Introducing Ardent ... for transformative growth, , Known as MediVet Biologics since its ... , The new Ardent Animal Health will build on its base of ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the leading global provider of advanced delivery technologies, development, and manufacturing solutions for ... they have entered into a strategic partnership whereby Catalent will provide support for ...
(Date:7/18/2020)... , ... July 16, 2020 , ... After research model ... completion of a great surgery is only the beginning of a successful study, while ... community. , Join Brad Gien, Global Head of Surgery from Envigo in ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Institute of Technology (MIT) has expanded the company’s exclusive license to include ... into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. ...
Breaking Biology Technology:
Cached News: